public record of the arguments and assumptions underlying the Government's handling of social services expenditure. Nowhere else are ministers and their senior civil servants questioned so closely and so publicly about their activities or their replies evaluated so critically. Secondly, the report shows the urgent need, in evaluating health and social service policies, of thinking simultaneously about costs and benefits. Without a coherent set of objectives and the means to measure the degree of their attainment questions about the effectiveness and efficiency of services cannot be answered rigorously. As the Committee put it, "Our underlying question is: What is the NHS trying to do, and what is the relationship between expenditure plans and the Government's policy objectives ?" And while the committee was not particularly impressed with the quality of the replies it received at the first time of asking it clearly intends to pursue the matter. As it remarked, rather tartly, "We look forward to obtaining a more enlightening response from the department when next we inquire." 5 since it was more a trial of systematic versus unsystematic medical care of blood pressure in the population than an exercise in clinical pharmacology. Half the patients with hypertension were referred to special clinics and received "stepped care" of their blood pressure along with advice on cigarette smoking, obesity, hypercholesterolaemia, and salt; the control patients were simply referred back to their normal medical services, and many received excellent treatment. The "stepped-care" group of mild hypertensives fared better, with fewer deaths, though no benefits were found in white women. Only data on mortality are available as yet, and a different picture may appear in the pattern of non-fatal complications. Whatever the outcome, this study seems unlikely to influence the treatment of mild hypertensives in Europe; its findings are relevant primarily to the American system of medicine.
The Australian National Blood Pressure Study6 I reported its preliminary results in 1979, and a more detailed description of the trial and its conclusions are now available.7 This was a more conventional clinical trial in which patients were randomly allocated to active or placebo treatment groups but otherwise received identical medical care. Statistically significant benefits from treatment were found only in patients whose diastolic pressures before treatment were 100 mm Hg or more. Furthermore, this treatment prevented both heart attacks and strokes. Until recently antihypertensive treatment had been thought not to prevent coronary heart disease,8 9 but this seems no longer true, as both the American and the Australian trials-and a recent study from Sweden10-have shown that heart attacks were prevented in the treated patients. This may be because in milder hypertensives arterial damage is less than in severe hypertensives so that early treatment may prevent further deterioration. The previous failures to prevent coronary disease may simply have been because treatment was started too late-when hypertensive vascular damage was too far advanced. This evidence suggests that the one million middleaged citizens of Britain with mild hypertension do require drug treatment, since this will prevent both heart attacks and strokes.
The mild hypertension story is, however, not over. 
Uraemic pruritus
Pruritus is not a feature of acute renal failure but is common in severe chronic renal failure, the reportedl-3 incidence being as high as 86"0. Many factors have been incriminated. Patients commonly have a dry skin (xerosis), and this may contribute to the pruritus. The xerosis may be related to the atrophy of the sebaceous glands4 and the eccrine sweat glands that occurs in uraemia.' The disturbances of calcium and phosphorus metabolism in chronic renal failure have also been implicated,1 6-9 while other possible factors include the proliferation of mast cells in the skin of some patients with uraemia,10 the high serum concentrations of magnesium,1' and an association with uraemic neuropathy.12 With so many possibilities the only certainty is that the mechanism of uraemic pruritus remains unknown.
Regular and intensive haemodialysis is said to cure or improve pruritus in many patients,13 14 Among the empirical treatments that have been commended is regular intravenous heparin for several weeks; good results were claimed but these were uncontrolled observations.'8 A double-blind trial comparing intravenous lignocaine with placebo saline during haemodialysis showed an improvement in the patients given the drug.3 Oral cholestyramine gave good results in one controlled trial'9 but not in another20-and cholestyramine carries a possible risk of inducing or aggravating a metabolic acidosis in uraemic patients.21 Ultraviolet phototherapy has also been tried22 23 and was effective in a controlled trial. 22 Pruritus is a notoriously difficult symptom to assess, and in all these trials with lignocaine, cholestyramine, and ultraviolet phototherapy the numbers were small; but these treatments may be worth trying in patients with intractable itching. A final note of caution: patients with severe uraemia are not immune from other causes of pruritus, such as scabies.
Sterilisation of mentally retarded minors
Severe mental handicap in a child is always a heavy burden for parents, but the circumstances are especially distressing when a girl is approaching the reproductive years. The risk of pregnancy is greater now than in the past, when more of these girls were cared for in single-sex institutions. There is an understandable concern to protect the youngster from pregnancy, and the parents may well seek medical advice and help. Some form of contraception may be offered, but at this age and in these circumstances none is really satisfactory. The two obvious choices-an intrauterine device and an injectable
